Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.
Abbott Laboratories (NYSE:ABT) secured US and European clearance for its Ultreon 3.0 AI-powered coronary imaging platform, aimed at improving decision support during stent placement.
The company received CE Mark in Europe for Libre Duo, a dual continuous glucose-ketone sensor designed for more comprehensive diabetes management.
Abbott plans to present new evidence on its cancer diagnostics portfolio at the ASCO Annual Meeting, focusing on early detection and treatment guidance.
Updated...
Kingsoft Cloud Holdings (NasdaqGS:KC) opened Q1 2026 with revenue of C¥2.7b and a basic EPS loss of C¥1.13. Trailing twelve month figures show revenue of C¥10.3b and a cumulative EPS loss of C¥3.36. Over recent quarters the company has reported revenue of C¥2.2b in Q4 2024, C¥2.0b in Q1 2025 and C¥2.7b in Q1 2026. Quarterly EPS losses ranged from C¥0.80 in Q4 2024 to C¥1.71 in Q2 2025 and C¥1.13 in the latest quarter, highlighting how efficiently revenue may eventually translate into...
Capri Holdings (CPRI) just wrapped FY 2026 with Q4 revenue of US$796 million and a small loss, with basic EPS coming in at US$0.01, while on a trailing twelve month basis EPS was US$0.66 on revenue of US$3.5 billion. Over the past few quarters, revenue has moved between US$797 million and US$1.0 billion, with quarterly EPS ranging from a loss of US$0.28 to a profit of US$0.48, giving investors a mixed but improving read on profitability. Overall, the latest print points to tight margins and...
Many investors are considering whether Albemarle's current share price fairly reflects its potential, or if the stock might be mispriced.
The stock recently closed at US$177.47, with a 4.3% gain over the past 7 days, a decline of 11.1% over the past 30 days, and returns of 23.3% year to date and 211.1% over the last year.
Recent headlines around Albemarle have kept attention on the stock, and investors are closely watching how broader sentiment toward materials and battery related companies...
Lam Research (NasdaqGS:LRCX) is in focus as AI driven demand for advanced chips supports multiyear capacity expansion plans at major memory producers.
Micron has outlined a multiyear, multibillion dollar investment program, signaling sustained equipment needs that could directly involve suppliers like Lam Research.
This reflects a broader industry shift toward higher AI related chip output, which is expected to influence Lam Research's order pipeline over several years.
Lam Research enters...
Meta Platforms is reported to have pulled back from bidding on key non-IDFA iOS mobile ad inventory.
This change directly affects a core segment of AppLovin's AXON AI ad platform business.
The shift gives AppLovin (NasdaqGS:APP) more room to compete for this traffic without head-to-head bidding from Meta.
AppLovin runs a large mobile advertising and app monetization platform, with AXON AI focused on matching ads to users across iOS and other ecosystems. With a major competitor stepping back...
Recently, analyst outlet StockStory flagged Crown Holdings as a stock to avoid, citing limited growth potential, slower earnings progress than peers, and pressure on gross margins from elevated input costs.
The critique also argues that Crown’s large scale could actually constrain its flexibility, potentially giving smaller packaging rivals a competitive edge in capturing growth.
We’ll now examine how concerns about high input costs and margin pressure may alter Crown Holdings’ existing...
Royalty Pharma recently reported strong first-quarter 2026 results, highlighting double-digit growth in portfolio and royalty receipts and continued expansion of its more than 35 marketed therapies and 20 development-stage assets.
At the same time, the company has been drawing increased investor interest as a major buyer of biopharmaceutical royalties, using collaborations in areas such as oncology, rare disease and neuroscience to reinforce confidence in its long-term cash flow...
Modine Manufacturing (MOD) just closed out FY 2026 with Q4 revenue of US$954.4 million and basic EPS of US$1.36, alongside trailing 12 month revenue of US$3.2 billion and EPS of US$2.26. These results reflect a year shaped by both solid quarterly profits and a large one off loss. Over recent periods, the company has seen quarterly revenue move from US$647.2 million with EPS of US$0.92 in FY 2025 Q4 to FY 2026 quarterly figures ranging between US$682.8 million and US$954.4 million. Over the...
Veradigm (MDRX) has just put fresh numbers on the table for FY 2024, with trailing 12 month revenue of US$594.4 million and a reported loss of US$291.5 million, alongside basic EPS of US$2.7 in the red. This sets a clear backdrop of revenue scale paired with negative earnings. The company has seen trailing revenue hold in a tight band between US$588.0 million and US$625.9 million over recent periods, while net income swung from a profit of US$49.2 million to a loss of US$291.5 million. This...
Hippocratic AI has reached 10 million patient calls on DigitalOcean’s AI-Native Cloud, in collaboration with NVIDIA.
The milestone comes from production use in healthcare, a sector that relies on high reliability and safety.
The partnership gives DigitalOcean Holdings (NYSE:DOCN) direct exposure to real world AI workloads beyond test or pilot projects.
For investors tracking NYSE:DOCN, this healthcare milestone sits at the intersection of cloud infrastructure and applied AI. DigitalOcean is...
